Table 3.
Drug resistance and mutations of newly reported HIV infections in Hefei from 2017 to 2020.
| Antiretroviral Drug | Number | % | HIV Drug Resistance Mutations (n, %) |
|---|---|---|---|
| Total | 52 | 6.4 | |
| PIs | 16 | 2.0 | |
| ATV | 1 | 0.1 | D30N (1, 0.1), K20T (2, 0.2), L10F (1, 0.1), L90M (1, 0.1), M46I (7, 0.9), Q58E (7, 0.9) |
| FPV | 2 | 0.2 | |
| IDV | 1 | 0.1 | |
| LPV/r | 1 | 0.1 | |
| NFV | 9 | 1.1 | |
| SQV | 1 | 0.1 | |
| TPV | 7 | 0.9 | |
| NRTIs | 10 | 1.2 | |
| ABC | 8 | 1.0 | A62V (2, 0.2), D67N (2, 0.2), K219E/R (3, 0.4), K65R (1, 0.1), K70T (1, 0.1), L74L/V (2, 0.2), M184V (4, 0.5), T215I (1, 0.1), T69DN (1, 0.1) |
| AZT | 2 | 0.2 | |
| D4T | 4 | 0.5 | |
| DDI | 6 | 0.7 | |
| FTC | 5 | 0.6 | |
| 3TC | 5 | 0.6 | |
| TDF | 2 | 0.2 | |
| NNRTIs | 31 | 3.8 | |
| DOR | 8 | 1.0 | V179E/D/T (101, 12.4), K103N (11, 1.3), V106I/M (11, 1.3), V108I (4, 0.5), E138G/A/Q (5, 0.6), Y181H/C (3, 0.3), G190S (1, 0.1), K101E (1, 0.1), P225H (1, 0.1), F227L (1, 0.1), H221Y (1, 0.1) |
| EFV | 20 | 2.5 | |
| ETR | 8 | 1.0 | |
| NVP | 25 | 3.1 | |
| RPV | 13 | 1.6 |
PIs, protease inhibitors; NRTIs, nucleoside reverse transcriptase inhibitors; NNRTIs, non-nucleoside reverse transcriptase inhibitors. ATV, atazanavir; FPV, fosamprenavir; IDV, indinavir; LPV/r, lopinavir/ritonavir; NFV, nelfinavir; SQV, saquinavir; TPV, tipranavir; ABC, abacavir; AZT, zidovudine; D4T, stavudine; DDI, didanosine; FTC, emtricitabine; 3TC, lamivudine; TDF, tenofovir disoproxil; DOR, dorivirine; EFV, efavirenz; ETR, etravirine; NVP, nevirapine; RPV, rilpivirine.